HealthQuill Drugs
Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy failed to show “sufficient evidence” of benefit to the patients.
Drugs Health Pharma

J & J stops rheumatoid arthritis trial due to lack of ‘sufficient evidence’

Johnson & Johnson has stopped a mid-trial evaluation of a combination drug to treat people with a type of arthritis after the therapy.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in females above 12 years and older, weighing at least 40 kilograms.
Drugs Health Pharma

GSK drug gets Britain’s nod to treat UTI patients 12 years and above

Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in.

Read More
Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.
Drugs Health Pharma

Biogen’s drug to treat postnatal depression gets UK regulator’s nod

Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.

Read More
The Food and Drug Administration has approved Pfizer Inc.’s treatment for metastatic non-small cell lung cancer.
Drugs Health

Implant TAR-200 eliminates bladder cancer in over 80% of high-risk cases in trials

HQ Team August 18, 2025: An implant called TAR-200 has shown remarkable results in treating high-risk bladder cancer. According to a recent Phase.

Read More
Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in people born in 1990 than in 1995, a study reveals.
Drugs Pharma Research

Immunotherapy drug shows promising results against metastatic cancers

HQ Team August 16, 2025: Phase I clinical trial of the CD40 agonist antibody drug 2141-V11, developed by Rockefeller University’s Jeffrey V. Ravetch.

Read More
Patients with cancer are markedly insulin-resistant, similar to people with type 2 diabetes, and it can lead to cancer spreading faster, according to a study by researchers at the University of Copenhagen.
Drugs Health

New pancreatic cancer vaccine shows promise in preventing recurrence in trial-1

HQ Team August 12, 2025: A new study published in the journal Nature Medicine has shown promising results for an experimental vaccine, ELI-002.

Read More
Novartis AG, a global Switzerland-based pharmaceutical company, has agreed to pay Monte Rosa Therapeutics Inc., $150 million upfront to develop, manufacture and commercialise drug candidates, mainly in immunology.
Drugs Research

Novartis’s Ianalumab has positive Phase III results for Sjögren’s Syndrome

HQ Team August. 11, 2025: Novartis AG announced positive Phase III trial results for its experimental autoimmune drug, Ianalumab (VAY736), in treating Sjögren’s.

Read More
Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.
Drugs Health Pharma

Jazz Pharma’s oral drug for a type of brain tumour gets US approval 

Jazz Pharmaceuticals Plc’s treatment for a rare and aggressive brain tumour that affects children and adults got approval from the US regulator.

Read More
The Gates Foundation will support more than 40 innovations in five chronically underfunded areas in women’s health by spending $2.5 billion over the next five years.
Drugs Health Pharma

Gates Foundation to spend $2.5 billion on women’s health innovations

The Gates Foundation will support more than 40 innovations in five chronically underfunded areas in women’s health by spending $2.5 billion over the.

Read More
The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious kidney diseases.
Drugs Health Pharma

FDA approves Apellis’ therapy to treat two serious, rare kidney diseases

HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious.

Read More